<DOC>
	<DOCNO>NCT02054663</DOCNO>
	<brief_summary>After heart attack patient routinely start drug inhibit platelet . Ticagrelor powerful anti-platelet drug clinical benefit . However must discontinue , increase risk bleed intolerance . These patient need transition another agent , Clopidogrel . At present , clinical consensus optimal strategy switch . Some clinician elect give bolus dose clopidogrel 600mg , others start directly 75mg daily dose , evidence regard benefit potential complication associate strategy . The present proposal evaluate pharmacodynamics 2 strategy specialize platelet function test . We hypothesize bolus dose clopidogrel switch confer good ischemic protection without increase bleed risk patient undergoing switch therapy .</brief_summary>
	<brief_title>Transition From Ticagrelor Clopidogrel Following Acute Coronary Syndrome : To Bolus Not ?</brief_title>
	<detailed_description>The overall objective evaluate need clopidogrel bolus dose among patient switch regimen ticagrelor clopidogrel . In randomized pharmacodynamics study 48 patient , conduct serial measurement platelet function/inhibition use Accumetrics Verifynow assay ( platelet inhibition express P2Y12 reaction unit [ PRU ] ) . Platelet inhibition assess specific time point first 72 hour follow change medication , enable u determine whether patient 2 different strategy may increase ischemic bleeding risk . We hypothesize bolus dose clopidogrel switch confer good ischemic protection without increase bleed risk patient undergoing switch therapy . SPECIFIC AIMS : 1 . Primary Aim : To determine platelet function test pharmacodynamics effect 600mg bolus dose clopidogrel compare bolusing among patient switch ticagrelor clopidogrel . 2 . To determine patient receive clopidogrel bolus improvement ischemic protection relative patient without bolus dose . 3 . To determine patient receive clopidogrel bolus may expose increase bleeding risk relative without bolus dose .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>age &gt; 18 , admission acute coronary syndrome , dual antiplatelet therapy ( include ticagrelor ) Being transition clopidogrel treat physician provide informed consent Bleeding/intolerance clopidogrel Thrombocytopenia ( platelet count &lt; 100 , 000 per uL ) Hematocrit &lt; 30 % &gt; 52 % treatment glycoprotein IIb/IIIa inhibitor , 24 hour prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>